Abstract
Summary The proposed study will identify microbial communities associated with flare ups and remissions of MEBO (systemic malodor of metabolic origin) or PATM (“People allergic to me”) conditions.
Background Human odor-prints, mostly owing to the microbiome, have proven their value as biomarkers of health and environmental exposures.
In recent years, microbial networks responsible for localized malodors (e.g., halitosis [1,2], groin area, foot and axillary odor [3,4]) have been mapped by using next generation sequencing approaches.
Intestinal microbes responsible for psychologically debilitating systemic malodor (whole-body and extraoral halitosis), however, remain to be identified. Even a relatively straightforward disorder of choline metabolism trimethylaminuria (TMAU) is thought to exhibit complex host-gene microbiome interactions [5] and has not been sufficiently studied.
Mapping gut microbiome is needed to understand human metabolic disfunction, make proper dietary recommendations and develop targeted treatments such as microbial therapies [6–8]. Our preliminary analysis of culture-, PCR- and 16S-RNA-based data found several Operational Taxonomic Units (OTUs) potentially linked to systemic malodor. Proposed controlled pilot study will provide a more comprehensive evaluation and, combined with our prior data [9–12], will help to develop new therapies and treatments.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03582826
Funding Statement
The author, on behalf of Public Charity MEBO Research, was awarded a grant in microbiome research support by uBiome through their Microbiome Grant Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Application and the Protocol Narrative with all applicable attachments was submitted to MEBO Research Institutional Review Board (IRB) on March 6, 2018 and approved on May 11, 2018. Protocol Number: 201805110018MEBO
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and materials will be made available upon reasonable request.
